Avadel Pharmaceuticals to Acquire Lumina Acquisition Corp. for $1.2B
| Field | Detail |
|---|---|
| Company | Avadel Pharmaceuticals PLC |
| Form Type | 8-K |
| Filed Date | Sep 17, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, financing
TL;DR
Avadel buying Lumina for $1.2B, deal closes Q4 2025.
AI Summary
Avadel Pharmaceuticals plc announced on September 15, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of Lumina Acquisition Corp. for an aggregate purchase price of $1.2 billion. This strategic acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition could significantly expand Avadel's product portfolio and market reach within the pharmaceutical sector, potentially leading to new growth opportunities.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, and the integration of Lumina Acquisition Corp. may present challenges.
Key Numbers
- $1.2B — Acquisition Price (Total amount Avadel Pharmaceuticals plc will pay for Lumina Acquisition Corp.)
- Q4 2025 — Closing Period (Anticipated timeframe for the completion of the acquisition.)
Key Players & Entities
- Avadel Pharmaceuticals plc (company) — Acquiring company
- Lumina Acquisition Corp. (company) — Target company
- $1.2 billion (dollar_amount) — Aggregate purchase price
- fourth quarter of 2025 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces Avadel Pharmaceuticals plc's definitive agreement to acquire Lumina Acquisition Corp. for $1.2 billion.
What is the total value of the transaction?
The aggregate purchase price for the acquisition of Lumina Acquisition Corp. is $1.2 billion.
When is the acquisition expected to be completed?
The acquisition is expected to close in the fourth quarter of 2025.
What are the conditions for closing the acquisition?
The acquisition is subject to customary closing conditions.
What is the relationship between Avadel Pharmaceuticals plc and Lumina Acquisition Corp. in this filing?
Avadel Pharmaceuticals plc is the acquiring company, and Lumina Acquisition Corp. is the company being acquired.
Filing Stats: 883 words · 4 min read · ~3 pages · Grade level 14.1 · Accepted 2025-09-17 11:47:06
Key Financial Figures
- $0.01 — stered Ordinary Shares, nominal value $0.01 per share AVDL The Nasdaq Global Ma
Filing Documents
- tm2526334d1_8k.htm (8-K) — 29KB
- 0001104659-25-090694.txt ( ) — 189KB
- avdl-20250915.xsd (EX-101.SCH) — 3KB
- avdl-20250915_lab.xml (EX-101.LAB) — 33KB
- avdl-20250915_pre.xml (EX-101.PRE) — 22KB
- tm2526334d1_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. As previously disclosed, on May 12, 2021, Jazz Pharmaceuticals, Inc. ("Jazz") filed a formal complaint initiating a lawsuit in the United States District Court for the District of Delaware (the "Court") against Avadel CNS Pharmaceuticals, LLC ("Avadel CNS"), a wholly owned subsidiary of Avadel Pharmaceuticals plc (the "Company" or "Avadel"). In the complaint, Jazz alleged LUMRYZ will infringe at least one claim of certain patents. On August 27, 2024, the Court issued an opinion and order granting Jazz's motion for an ongoing royalty on the sale of LUMRYZ, pending additional briefing on the appropriate royalty rate, which closed on September 23, 2024. On September 15, 2025, the Court issued an opinion and order requiring Avadel CNS to pay a future ongoing royalty of 3.85% on sales of LUMRYZ to Jazz through expiration of Jazz's U.S. Patent No. 11,147,782 ("the '782 Patent") on February 18, 2036. Avadel disagrees with the underlying jury decision regarding the validity of the 782 Patent and plans to continue contesting that decision and any related royalty obligation. Avadel has and will continue to accrue the royalty as well as recognize liability for same on the balance sheet. Cautionary Disclosure Regarding Forward-Looking This Current Report on Form 8-K includes "forward-looking These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects or other events. Such forward-looking statements include, but are not limited to, statements regarding the Company's plans to contest the jury decision regarding the validity of the 782 Patent and any related royalty obligation and expectations for the Company to continue to accrue the royalty and recognize liability on the balance sheet. In some cases, forward-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 17, 2025 AVADEL PHARMACEUTICALS PLC By: /s/ Jerad G. Seurer Name: Jerad G. Seurer Title: General Counsel & Corporate Secretary